The evidence for vaccine safety and efficacy exists in overwhelming abundance, accessible to anyone willing to examine it.

Company Underscores Rigorous Safety Monitoring and Long History of the MVA Platform as Development of GEO-CM04S1 Advances ...

Preliminary analysis showed the 2025-2026 formula of mNEXSPIKE generated greater than a 16-fold increase in LP.8.1-neutralizing antibodies across age groups Both of Moderna’s COVID-19 vaccines for the ...

Moderna Inc. (NASDAQ:MRNA) on Tuesday released preliminary immunogenicity data for the 2025-2026 formula of mNEXSPIKE ...

The vaccine advisory committee is scheduled to meet next week to review and make recommendations for this fall’s updated ...

Moderna's updated Spikevax shows strong antibody response and safety, targeting dominant COVID-19 variants like LP.8.1 in high-risk and older adults.

Vaccine makers’ shares fell after a report that Trump health officials plan to link Covid shots to the deaths of around two dozen children in a presentation to advisers to the Centers for Disease ...

Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 4% in the morning session after the company announced positive ...

Known as the Vaccine Adverse Event Reporting System ... In an emailed statement, the CDC tells NPR the agency is aware of the misuse of the VAERS data but has no immediate plans to change the system.